Alpha 2-macroglobulin in patients with inflammatory bowel disease

Area of Science:

• Biochemistry
• Immunology
• Gastroenterology

Background:

• Alpha 2-macroglobulin (alpha 2-M) is a major human protease inhibitor.
• Inflammatory bowel disease (IBD) encompasses Crohn's disease and ulcerative colitis, characterized by chronic inflammation of the gastrointestinal tract.

Purpose of the Study:

• To investigate alpha 2-macroglobulin (alpha 2-M) levels in patients with ulcerative colitis and Crohn's disease.
• To compare alpha 2-M concentrations and cell surface expression in patients with IBD and healthy controls.

Main Methods:

• Serum samples were collected from patients with active IBD and normal controls.
• Concentrations of alpha 2-M were measured in serum.
• The proportion of mononuclear cells expressing alpha 2-M on their surface was analyzed.
• Alpha 2-M presence in rectal tissue was assessed.

Main Results:

• Serum alpha 2-M concentrations were significantly lower in patients during the active phase of ulcerative colitis and Crohn's disease compared to controls.
• No correlation was found between alpha 2-M levels and other clinical features of the diseases.
• The proportion of mononuclear cells bearing alpha 2-M did not differ between IBD patients and controls.
• Alpha 2-M was undetectable in rectal tissue samples from both patients and controls.

Conclusions:

• A decrease in serum alpha 2-M occurs during active inflammatory bowel disease, which was an unexpected finding.
• Protein loss from the inflamed intestine is unlikely to explain the reduced alpha 2-M levels.
• Further metabolic studies are required to determine the reasons for altered synthesis or catabolism of alpha 2-M in IBD.